Antibody-Drug Conjugates (ADC)

Boehringer Ingelheim Opens New R&D Center in Basel

NBE Therapeutics (NBE), a wholly owned subsidiary of  Boehringer Ingelheim, officially opened its new ADC R&D facility in Basel.

HAS Acquires Cerbios-Pharma

HAS Healthcare Advanced Synthesis (HAS) recently announced the planned acquisition of Cerbios-Pharma (Cerbios), a globally recognized manufacturer of chemical and biological APIs, including antibody-drug conjugates (ADCs).

Axplora Expands Capabilities at Le Mans Site

Axplora, an API small molecule and ADC (antibody-drug conjugate) manufacturer, is strengthening its position in the commercial manufacturing ADCs by launching a cutting-edge payload manufacturing workshop at its Le Mans site (France).

Samsung Biologics Signs Manufacturing Deal with European Pharmaceutical Company

Samsung Biologics, a global contract development and manufacturing organization (CDMO), recently announced a series of manufacturing deals with a Europe-based pharmaceutical company.

Lonza to Expand Bioconjugation in Visp, Switzerland

Lonza, a global contract development and manufacturing organization (CDMO) for the pharmaceutical, biotech, and nutraceutical markets, announced today that it will invest in additional bioconjugation capabilities in Visp, Switzerland.

Sterling Pharma Solutions Expands GMP ADC Manufacturing Capacity

Sterling Pharma Solutions, a global contract development and manufacturing organization (CDMO), today announced the second phase of an expansion strategy at its Deeside, UK site to support antibody-drug conjugate (ADC) development, with a more than £10 million (€11.9 million) investment to increase GMP bioconjugation capacity.

Daiichi Sankyo and MSD Expand Global Collaboration

Japan's Daiichi Sankyo and US drugmaker MSD have expanded their existing global co-development and co-commercialization agreement for three investigational DXd antibody drug conjugates to include MSD’s MK-6070, a compound MSD obtained through its recent acquisition of Harpoon Therapeutics.

Johnson & Johnson to Acquire Ambrx

Johnson & Johnson has entered into a definitive agreement to acquire Ambrx, a clinical-stage biopharmaceutical company with a proprietary synthetic biology technology platform to design and develop next-generation antibody-drug conjugates (ADCs). The all-cash merger transaction for a total equity value of approximately €1.8 billion ($2.0 billion), or €1.75 billion ($1.9 billion) net of estimated cash acquired.

Daiichi Sankyo and Merck & Co. Collaborate on Three DXd ADCs Worldwide

Daiichi Sankyo and Merck & Co. to co-develop and commercialize three of Daiichi Sankyo’s DXd antibody-drug conjugate (ADC) candidates worldwide except for Japan where Daiichi Sankyo retains exclusive rights. Merck to pay Daiichi Sankyo up to €20.8 billion for the collaboration.

EU Commission Approves Pfizer’s Takeover of Seagen

The US pharmaceutical company Pfizer has been cleared to acquire Seagen, a biotech company focused on developing cancer treatments.

Lonza Increases Capacity for Antibody-Drug Conjugates at Visp, Switzerland

Swiss contract development and manufacturing organization (CDMO) Lonza is extending a long-term collaboration with an unnamed major global biopharmaceutical partner. Under the agreement, the current dedicated bioconjugation capacity will be increased fourfold by adding two new bioconjugation suites for the commercial supply of antibody-drug conjugates (ADCs) at Lonza's site in Visp, Switzerland.

Wuxi Biologics Plans Spin-off and Separate Listing of Wuxi XDC

Chinese contract research, development, and manufacturing organization (CRDMO) Wuxi Biologics announced the planned spin-off and separate listing of its subsidiary WuXi XDC on the Hong Kong Stock Exchange. Upon completion of the proposed listing, Wuxi XDC will remain a consolidated subsidiary.

Olon Builds Second Plant for Ultra-Potent Compounds

Italian API producer Olon has started building a second facility at its Rodano site in Milan that will be entirely dedicated to producing ultra-potent compounds.

BioNTech and DualityBio Sign ADC Rights Deal

German biotech and Covid vaccine maker BioNTech has sealed a major deal with Chinese biotech DualityBio to co-develop and commercialize two cancer antibody drug candidates (ADCs).

Pfizer Takes Seagen for $43 Billion

Pfizer has agreed to acquire Seagen, a global biotech focused on developing cancer treatments, for $43 billion. The announcement comes just a couple of weeks after the Wall Street Journal reported that the two companies were in talks.

Integrated Drug Development Models

Interview with Giovanna Libralon, Senior Director Commercial Development Small Molecules at Lonza.

Managing Supply for Complex Biotherapeutics

Successfully managing the drug substance manufacturing of Antibody-Drug Conjugates (ADCs) requires a sophisticated understanding of the technological development process and access to a range of large- and small-molecule manufacturing assets.

Catalent and Exelixis Link on ADCs

US-based CDMO Catalent is joining forces with compatriot drug discovery company Exelixis to develop multiple antibody-drug conjugates (ADCs). The company’s Redwood Bioscience subsidiary will use its proprietary SMARTag site-specific bioconjugation technology to build ADCs using monoclonal antibodies from Exelixis’ preclinical pipeline.

The Rise of HPAPI Molecules

For biopharma leaders it is more critical than ever to secure the capabilities to contain, handle, develop and manufacture highly potent APIs.

ADC Bio to Invest $11m on Bioconjugation Facility

Glythera Launches ADC Project

The Winning Formula

Cerbios joins CMC Biologics and IDT Biologika in ADC Collaboration

Opportunities in Drug Development and Manufacturing

Growth in the global oncology drug market is an important measure of opportunities in drug development and manufacturing, including for contract manufacturers of active pharmaceutical ingredients (APIs) and finished drug products.

The Winning Formula

Bridging the Innovation Gap

India’s Piramal Healthcare Invests in Scotland

Merck Serono and Sutro to Collaborate on ADCs

Carbogen Amcis to Take Over High-Containment Facility

Merck Serono and Mersana Collaborate on Antibody Drug Conjugates

Roche to Spend $880 Million on Manufacturing, Create 500 Jobs

Chemical Industry’s Expectations for the U.S. Business Climate in 2013

Fujifilm Diosynth Biotechnologies, Piramal Announce Strategic Alliance

Manufacturing of HPAPIs and ADC Toxins for the Drugs of Tomorrow

Fine Chemicals: The Top 10